MY135627A - Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl) -piperazine and its physiologically acceptable salts - Google Patents

Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl) -piperazine and its physiologically acceptable salts

Info

Publication number
MY135627A
MY135627A MYPI20002314A MYPI20002314A MY135627A MY 135627 A MY135627 A MY 135627A MY PI20002314 A MYPI20002314 A MY PI20002314A MY PI20002314 A MYPI20002314 A MY PI20002314A MY 135627 A MY135627 A MY 135627A
Authority
MY
Malaysia
Prior art keywords
cyanoindol
benzofuran
carbamoyl
butyl
piperazine
Prior art date
Application number
MYPI20002314A
Other languages
English (en)
Inventor
Bartoszyk Gerd
Seyfried Dr Christoph
Amsterdam Dr Van Christoph
Bottcher Dr Henning
Sedman Ewen
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY135627(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MY135627A publication Critical patent/MY135627A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MYPI20002314A 1999-05-27 2000-05-25 Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl) -piperazine and its physiologically acceptable salts MY135627A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99109295 1999-05-27

Publications (1)

Publication Number Publication Date
MY135627A true MY135627A (en) 2008-05-30

Family

ID=8238153

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20002314A MY135627A (en) 1999-05-27 2000-05-25 Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl) -piperazine and its physiologically acceptable salts

Country Status (31)

Country Link
US (4) US6900212B1 (https=)
EP (3) EP1185272B1 (https=)
JP (2) JP4884588B2 (https=)
KR (1) KR100683367B1 (https=)
CN (3) CN101869565A (https=)
AR (1) AR024112A1 (https=)
AT (3) ATE438399T1 (https=)
AU (1) AU771778B2 (https=)
BR (1) BR0010948A (https=)
CA (3) CA2694866A1 (https=)
CY (2) CY1105750T1 (https=)
CZ (1) CZ295623B6 (https=)
DE (3) DE60042710D1 (https=)
DK (3) DK1410800T3 (https=)
ES (3) ES2271707T3 (https=)
HK (1) HK1048444B (https=)
HU (1) HU229059B1 (https=)
IL (2) IL146707A0 (https=)
MX (1) MXPA01012172A (https=)
MY (1) MY135627A (https=)
NO (2) NO322120B1 (https=)
PL (3) PL200490B1 (https=)
PT (3) PT1736158E (https=)
RU (1) RU2237477C2 (https=)
SI (2) SI1185272T1 (https=)
SK (1) SK287851B6 (https=)
TR (1) TR200103361T2 (https=)
TW (1) TW518218B (https=)
UA (1) UA74337C2 (https=)
WO (1) WO2000072832A2 (https=)
ZA (1) ZA200110485B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
UA76130C2 (en) * 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
DE10112151A1 (de) * 2001-03-14 2002-09-19 Merck Patent Gmbh Substituierte Benzofuran-2-carbonsäureamide
UA76758C2 (uk) 2001-06-19 2006-09-15 Мерк Патент Гмбх Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
DE10305739A1 (de) * 2003-02-11 2004-08-19 Merck Patent Gmbh Benzofuranderivate
WO2004082686A2 (en) * 2003-03-13 2004-09-30 Dynogen Pharmaceuticals, Inc. Use of compounds with combined 5-ht1a and ssri activities to treat sexual dysfunction
US7893261B2 (en) 2004-03-26 2011-02-22 Baylor University Serotonin reuptake inhibitors
WO2007138304A1 (en) 2006-05-30 2007-12-06 Astrazeneca Ab 1, 3, 4 -oxadiazole derivatives as dgat1 inhibitors
EP2234978B1 (en) 2007-12-20 2015-02-25 AstraZeneca AB Carbamoyl compounds as dgat1 inhibitors 190
BRPI1016109A2 (pt) 2009-06-19 2016-05-17 Astrazeneca Ab "composto, composição farmacêutica, e, processo para preparar um composto"
BR112012010670A2 (pt) 2009-11-06 2016-04-12 Sk Biopharmaceuticals Co Ltd métodos para tratamento de distúrbio de défict de atenção/hiperatividade
EP2496227B1 (en) * 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
US9708300B2 (en) 2011-03-20 2017-07-18 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for its preparation
CN102949364A (zh) * 2011-08-30 2013-03-06 天津药物研究院 一种含有效成分盐酸维拉佐酮的缓释片
US9382233B2 (en) 2012-06-13 2016-07-05 Apotex Inc. Forms of vilazodone and processes for the preparation thereof
CN102860993A (zh) * 2012-10-16 2013-01-09 北京诚创思达医药科技有限公司 一种盐酸维拉唑酮快速释放片剂及其制备方法
WO2014064715A2 (en) 2012-10-22 2014-05-01 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for preparing thereof
CN102977083A (zh) * 2012-12-17 2013-03-20 南京海纳医药科技有限公司 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的新晶型xⅶ及其制备方法
EP4385563A3 (en) 2013-01-22 2024-08-21 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses l-4-chlorokynurenine
EP2824104A1 (en) 2013-07-12 2015-01-14 Sandoz AG Process for the preparation of form III of Vilazodone hydrochloride
KR20240068766A (ko) * 2015-05-22 2024-05-17 비스타젠 쎄라퓨틱스, 인크. L-４-클로로키누레닌의 치료적 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672052B1 (fr) * 1991-01-28 1995-05-24 Esteve Labor Dr Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments.
SE9201239D0 (sv) * 1992-04-21 1992-04-21 Kabi Pharmacia Ab Agents for treating substance abuse disorders
DE4333254A1 (de) * 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
DE19514567A1 (de) 1995-04-20 1996-10-24 Merck Patent Gmbh Benzofurane
US5763457A (en) * 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5914394A (en) * 1997-03-27 1999-06-22 Millenium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
US6470933B1 (en) * 1998-03-09 2002-10-29 Pirelli Pneumatici S.P.A. Tire containing at least part of an electrical current generator intended for the supply of sensors and/or other electrical devices present within the tire, and method for manufacture the said tire
FR2781671A1 (fr) * 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
EP1291660A3 (en) * 2001-09-11 2003-05-28 Koyo Seiko Co., Ltd. Magnetic pulser ring, magnetizing device and method, and bearing unit having a magnetic pulser ring
FR2844591B1 (fr) * 2002-09-13 2005-04-15 Arvinmeritor Light Vehicle Sys Dispositif de determination du deplacement d'un arbre

Also Published As

Publication number Publication date
EP1736158A2 (en) 2006-12-27
CY1105750T1 (el) 2010-12-22
CZ295623B6 (cs) 2005-09-14
EP1410800A1 (en) 2004-04-21
DE60030338T2 (de) 2007-08-16
HUP0201275A2 (en) 2002-08-28
AR024112A1 (es) 2002-09-04
US7642261B2 (en) 2010-01-05
EP1185272A2 (en) 2002-03-13
PT1736158E (pt) 2009-11-11
HUP0201275A3 (en) 2004-04-28
HK1048444A1 (en) 2003-04-04
EP1736158A3 (en) 2007-01-03
ES2271707T3 (es) 2007-04-16
BR0010948A (pt) 2002-04-23
CA2372668C (en) 2009-11-03
PT1410800E (pt) 2007-01-31
TR200103361T2 (tr) 2002-05-21
KR100683367B1 (ko) 2007-02-15
EP1185272B1 (en) 2004-04-07
JP4884588B2 (ja) 2012-02-29
US20100063062A1 (en) 2010-03-11
HK1048444B (zh) 2005-12-09
CN1198618C (zh) 2005-04-27
CA2372668A1 (en) 2000-12-07
CA2615271A1 (en) 2000-12-07
PT1185272E (pt) 2004-08-31
SI1185272T1 (en) 2004-12-31
ZA200110485B (en) 2003-06-30
JP2003500441A (ja) 2003-01-07
PL200490B1 (pl) 2009-01-30
MXPA01012172A (es) 2002-07-22
NO20015746D0 (no) 2001-11-26
ES2330774T3 (es) 2009-12-15
CA2615271C (en) 2011-02-15
AU5066300A (en) 2000-12-18
CN1679577A (zh) 2005-10-12
DE60030338D1 (de) 2006-10-05
ATE263564T1 (de) 2004-04-15
NO20015746L (no) 2001-11-26
WO2000072832A2 (en) 2000-12-07
RU2237477C2 (ru) 2004-10-10
JP2011148799A (ja) 2011-08-04
IL146707A0 (en) 2002-07-25
DK1410800T3 (da) 2006-12-27
NO322120B1 (no) 2006-08-14
ATE438399T1 (de) 2009-08-15
DK1736158T3 (da) 2009-11-02
NO20061562L (no) 2001-11-26
EP1410800B1 (en) 2006-08-23
CA2694866A1 (en) 2000-12-07
DK1185272T3 (da) 2004-08-09
SK287851B6 (sk) 2012-01-04
EP1736158B1 (en) 2009-08-05
CN101869565A (zh) 2010-10-27
CN1361692A (zh) 2002-07-31
CY1109472T1 (el) 2012-05-23
PL199650B1 (pl) 2008-10-31
SK16462001A3 (sk) 2002-02-05
PL352373A1 (en) 2003-08-25
HU229059B1 (en) 2013-07-29
US20080119484A1 (en) 2008-05-22
DE60009697D1 (de) 2004-05-13
US7371756B2 (en) 2008-05-13
NO324230B1 (no) 2007-09-10
AU771778B2 (en) 2004-04-01
US20050113386A1 (en) 2005-05-26
US6900212B1 (en) 2005-05-31
KR20020008847A (ko) 2002-01-31
WO2000072832A3 (en) 2001-12-20
UA74337C2 (uk) 2005-12-15
ATE337008T1 (de) 2006-09-15
TW518218B (en) 2003-01-21
SI1410800T1 (sl) 2007-02-28
ES2219342T3 (es) 2004-12-01
CZ20014226A3 (cs) 2002-03-13
IL146707A (en) 2007-06-03
DE60009697T2 (de) 2005-04-14
PL199516B1 (pl) 2008-09-30
DE60042710D1 (de) 2009-09-17

Similar Documents

Publication Publication Date Title
MY135627A (en) Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl) -piperazine and its physiologically acceptable salts
NO20090229L (no) 1-[2-(2,4-dimetylfenylsulfanyl-fenyl]-piperazin som en forbindelse med kombinert serotoninreopptak, 5-HT3- og 5HT1A-aktivitet for behandlingen av kognitiv smerte
ATE174519T1 (de) Beatmungsgerät
EP2000462A3 (en) Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications
MEP6508A (xx) Fenil-piperazin derivati kao inhibitori resorbucije serotonina
NO20014103L (no) N-[2-hydroksy-3-(1-piperidinyl)propoksy]pyridin-1-oksid-3- karboksimidoylklorid og dets anvendelse for behandling avinsulinresistens
DK0810991T3 (da) 1-Aryl-2-acylamino-ethan-forbindelser og deres anvendelse som neurokinin- især neurokinin-1-antagonister
DE69927689D1 (de) Lipid-senkende chinazoline derivate
NO20035115D0 (no) 4-(fenylpiperidin-4-yliden-metyl)-benzamidderivater og deres anvendelse forbehandling av smerte, angst eller gastrointestinale forstyrrelser
HUP0101253A2 (hu) Új eljárás ketiminszármazék előállítására
ZA200309557B (en) Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethy)-1-piperindinyl]-1-hydroxybutyl]-alpha, alpha-dimethylbenzene acetic acid and its hydrochloride.
IL157929A0 (en) Method of producing n-substituted 2,6-dialkyl morpholines
WO2001080041A3 (en) Method and apparatus for detecting sleep disorders using the variability of the rr interval in an ecg waveform
DK1420788T3 (da) Nye piperidin-2,6-dion-bisulfatsalte og deres anvendelse til behandling af stressrelaterede emotionelle lidelser
MXPA04001030A (es) Proceso para la preparacion de isobenzofuranos 5-sustituidos.
DK1353906T3 (da) Fremgangsmåde til fremstilling af (3-cyano-1H-indol-7-yl)(4-(4-fluorphenetyl)piperazin-1-yl)-methanon og salte deraf
DE69935865D1 (de) Endothelin-niveau senkende mittel
DE50210727D1 (de) Verwendung von arzneimitteln enthaltend n, n'-disubstituierte piperazin-verbindungen
FR2757511B1 (fr) Procede pour la preparation d'un derive de tetrahydropyridine
HU9500453D0 (en) 1-[2-(1h-inden-3-yl)ethyl]-4-(naphtalen-1-yl)piperazine derivatives, process for preparing them and their medical use
ÑÏÐÀÂÈ ÇÀÃÀËÜͲ ÏÈÒÀÍÍß
WO2003045392A3 (de) Verwendung von n-(indolcarbonyl-)piperazinderivaten
WO2005113526A3 (en) Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one
RU2002112128A (ru) Способ хирургического лечения тяжелых форм юношеского эпифизеолиза головки бедренной кости при отсутствии синостозирования ростковой зоны
Komiya et al. The result of name-of-a-prefecture cognitive investigation of a schoolchild and its subject